StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > ⚡⚡⚡ SZLS should focus on Aristotle, forget covid tests

<< Previous

Bullboard Posts

Next >>

Comment by NewToInvesting7on May 12, 2021 12:49pm

102 Views

Post# 33183409

RE:RE:RE:⚡⚡⚡ SZLS should focus on Aristotle, forget covid tests

Competition might be cheaper, but SZLS is still making money for their Covid testing. And since travelers to certain destinations need a PCR test, and some places like Barbados require the test from SZLS (I think), to simply ignore that money on the table is foolish, if there is capacity, and if SZLS is not spending significant time or resources to market this Covid test.

Nobody is saying to not focus on Aristotle, but honestly, I do not think that they can solely focus on Aristotle and make revenues, especially if certain regulatory requirements are still to be met (like the clinics to treat those that have positive Cancer results). With the current state of the world, Cancer testing is not a priority. So focusing solely on Aristotle is not wise, especially when you can generate sufficient revenues from Covid testing to cover costs, while hopefully spending a majority of time and resources on Aristotle.

Cheers!

DobreCoffee wrote: Just look at the competition, price,etc... SZLS is way behind with covid tests (price)..... Who's going to pay $399 for 2 tests with szls??? The competition is a lot cheaper and faster, that being the reason SZLS should focus on Aristotle , ASAP .

NewToInvesting7 wrote: Respectfully disagree.

If SZLS could stop Covid testing today, and replace 100% of that lost revenues with Aristotle revenues, then maybe I can see it. However, I do not believe they are running the lab at 100% capacity, so no need for them to forget Covid tests. Simply continue with the Covid testing, and ramp up Aristotle testing. Once Aristotle testing is at a level that would require use of 100% of the lab, then stop with the Covid testing, if it would not impact long term partnerships - i.e., partners that use SZLS for both Aristotle and Covid testing.

Cheers!

DobreCoffee wrote:
More info at: https://www.businesswire.com/news/home/20210112005454/en/Calgary-Biotech-Company-%E2%80%9CCardiAI%E2%80%9D-Receives-Provincial-Regulatory-Approval-for-New-Laboratory